Growth and density-dependent regulation of NO synthase by the actin cytoskeleton in pulmonary artery endothelial cells.
We previously reported association of eNOS with actin increases eNOS activity. In the present study, regulation of activity of eNOS by actin cytoskeleton during endothelial growth was studied. We found eNOS activity in PAEC increased when cells grew from preconfluence to confluence. eNOS activity was much greater in PAEC in higher density than those in lower density, suggesting increase in eNOS activity during cell growth is caused by increase in cell density. Although eNOS protein contents were also increased when endothelial cells grew from preconfluence to confluence, magnitude of increase in eNOS activity was much higher than increase in eNOS protein content, suggesting posttranslational mechanisms played an important role in regulation of eNOS activity during endothelial growth. Confocal fluorescence microscopy revealed eNOS was colocalized with G-actin in preconfluent cells in perinuclear region, with both G-actin in perinuclear area and cortical F-actin in plasma membrane in confluent cells. There was more beta-actin coimmunoprecipitated with eNOS in Triton X-100-soluble fraction in confluent cells in later growth phase and in high density. Decrease in eNOS association with beta-actin by silencing beta-actin expression using beta-actin siRNA causes inhibition of eNOS activity, NO production, and endothelial monolayer wound repair in PAEC. Moreover, PAEC incubation with cytochalasin D and jasplakinolide resulted in increases in eNOS/actin association and in eNOS activity without changes in eNOS protein content. Yeast two-hybrid experiments suggested strong association between eNOS oxygenase domain and beta-actin. These results indicate increase in eNOS association with actin is responsible for greater eNOS activity in confluent PAEC.
Kondrikov
Dmitry
D
Department of Medicine, Universityof Florida College of Medicine, Gainesville, FL 32610, USA.
Han
Hye-Rim
HR
Block
Edward R
ER
Su
Yunchao
Y
D000199:Actins / Q000187:drug effects / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D000818:Animals; D002452:Cell Count; D002455:Cell Division / Q000502:physiology; D002478:Cells, Cultured; D015638:Cytochalasin D / Q000494:pharmacology; D003599:Cytoskeleton / Q000187:drug effects / Q000502:physiology*; D047630:Depsipeptides / Q000494:pharmacology; D042783:Endothelial Cells / Q000166:cytology / Q000201:enzymology* / Q000378:metabolism; D020868:Gene Silencing; D006801:Humans; D047468:Immunoprecipitation; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism*; D019384:Nucleic Acid Synthesis Inhibitors / Q000494:pharmacology; D011651:Pulmonary Artery / Q000166:cytology* / Q000201:enzymology* / Q000378:metabolism; D013552:Swine; D014018:Tissue Distribution; D020798:Two-Hybrid System Techniques; D015003:Yeasts
D000199:Actins; D047630:Depsipeptides; D019384:Nucleic Acid Synthesis Inhibitors; C057531:jasplakinolide; D015638:Cytochalasin D; D052250:Nitric Oxide Synthase Type III